Skip to content

What’s New?

ASIT 2020: What’s New?

As the field of antigen specific immunotherapies continues to grow, so too does the amount of content being shared each year at the ASIT Summit. To support your ever-changing needs, we present to you ASIT 2020 - and its bigger and better than ever before!

So What's New?

ASIT Bullet Point

More Speakers Than Ever Before
This year we have more industry leading speakers than ever before. Assembled from the autoimmune, oncology and allergy fields, ASIT 2020 is bringing together the largest number of industry KOL’s it has ever done to address the biggest challenges facing tolerance induction drug developers.

ASIT Bullet Point

More Biopharma Represented on the Speaking Panel Than Ever Before
At ASIT 2020, we have more Biopharma represented on our speaking agenda than ever before. With 25 representatives from biotech and large pharma presenting their latest findings, proof of concepts and clinical read outs, this is a meeting you simply cannot afford to miss. Gain insights and network with pioneers from Takeda, Pfizer, Novo Nordisk, Eli Lilly, Cour Pharmaceuticals and many more!

You Asked and We Listened!

Exclusively at ASIT 2020, We Present Our First Ever:

ASIT Bullet Point

Dedicated Clinical Readout Session
As clinical progress in the ASIT field rapidly builds momentum, we present our first ever conference session dedicated solely to hearing the latest clinical readouts. Hear from Cour Pharmaceuticals, Apitope, IM therapeutics & Selecta as they share data from clinical trials at the forefront of the field.

ASIT Bullet Point

Dedicated Tolerance Induction Session
In looking to overcome the key challenges to developing antigen specific immune tolerance therapeutics, it can be easy to get stuck in debates surrounding antigen discovery and delivery. Whilst both remain important issues, what really drives the efficacy of such clinical trials is the third access, successfully inducing tolerance. It is for this reason that ASIT 2020 has 3 hours of content dedicated to addressing the fundamental challenges behind tolerance induction so that you can more confidently determine the extent of induction and the durability of your response. Hear from the likes of Eli Lilly, Novo Nordisk, Tolerion and more!